Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immutep Ltd ( (AU:IMM) ) has shared an update.
Immutep Ltd has announced the quotation of 33,904 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 18, 2025. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially benefiting its stakeholders by increasing liquidity and visibility in the market.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments. The company is primarily engaged in creating therapies that modulate the immune system for cancer and autoimmune diseases.
Average Trading Volume: 3,221,289
Technical Sentiment Signal: Sell
Current Market Cap: A$350.5M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.